AU2003279456B2 - Combination product of inhibitor of the SRC family of non-receptor tyrosine kinases and gemcitabine - Google Patents

Combination product of inhibitor of the SRC family of non-receptor tyrosine kinases and gemcitabine Download PDF

Info

Publication number
AU2003279456B2
AU2003279456B2 AU2003279456A AU2003279456A AU2003279456B2 AU 2003279456 B2 AU2003279456 B2 AU 2003279456B2 AU 2003279456 A AU2003279456 A AU 2003279456A AU 2003279456 A AU2003279456 A AU 2003279456A AU 2003279456 B2 AU2003279456 B2 AU 2003279456B2
Authority
AU
Australia
Prior art keywords
chloro
mixture
methoxy
evaporated
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003279456A
Other languages
English (en)
Other versions
AU2003279456A1 (en
Inventor
Alan Barge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2003279456A1 publication Critical patent/AU2003279456A1/en
Application granted granted Critical
Publication of AU2003279456B2 publication Critical patent/AU2003279456B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Control And Other Processes For Unpacking Of Materials (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003279456A 2002-11-13 2003-11-07 Combination product of inhibitor of the SRC family of non-receptor tyrosine kinases and gemcitabine Ceased AU2003279456B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0226434.9A GB0226434D0 (en) 2002-11-13 2002-11-13 Combination product
GB0226434.9 2002-11-13
PCT/GB2003/004787 WO2004043472A1 (en) 2002-11-13 2003-11-07 Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine

Publications (2)

Publication Number Publication Date
AU2003279456A1 AU2003279456A1 (en) 2004-06-03
AU2003279456B2 true AU2003279456B2 (en) 2007-05-17

Family

ID=9947715

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003279456A Ceased AU2003279456B2 (en) 2002-11-13 2003-11-07 Combination product of inhibitor of the SRC family of non-receptor tyrosine kinases and gemcitabine

Country Status (16)

Country Link
US (1) US20060142297A1 (enExample)
EP (1) EP1562612B1 (enExample)
JP (1) JP2006508953A (enExample)
KR (1) KR20050074573A (enExample)
CN (1) CN100467027C (enExample)
AT (1) ATE456370T1 (enExample)
AU (1) AU2003279456B2 (enExample)
BR (1) BR0316170A (enExample)
CA (1) CA2504666A1 (enExample)
DE (1) DE60331162D1 (enExample)
ES (1) ES2338109T3 (enExample)
GB (1) GB0226434D0 (enExample)
NO (1) NO20052312L (enExample)
NZ (1) NZ539514A (enExample)
WO (1) WO2004043472A1 (enExample)
ZA (1) ZA200503805B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
NZ539408A (en) 2002-11-04 2007-09-28 Astrazeneca Ab Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
GB0412074D0 (en) 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
GB0427697D0 (en) 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
ES2556173T3 (es) 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
AU2008205847A1 (en) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
KR101445892B1 (ko) 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
WO2013152313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
WO2014185540A1 (en) 2013-05-14 2014-11-20 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
KR20250024102A (ko) 2015-02-25 2025-02-18 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 고미 억제 방법
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US20170022576A1 (en) 2015-03-18 2017-01-26 The Regents Of The University Of California Compositions and methods for identifying anti-cancer, anti-metastatic and anti-stress agents
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
US20200197384A1 (en) 2017-05-16 2020-06-25 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057271A2 (en) * 2000-10-23 2002-07-25 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the src family

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
AU762079B2 (en) * 1998-09-25 2003-06-19 Warner-Lambert Company Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
DE60006541D1 (de) * 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057271A2 (en) * 2000-10-23 2002-07-25 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the src family

Also Published As

Publication number Publication date
DE60331162D1 (de) 2010-03-18
AU2003279456A1 (en) 2004-06-03
EP1562612B1 (en) 2010-01-27
NZ539514A (en) 2007-11-30
CN100467027C (zh) 2009-03-11
WO2004043472A1 (en) 2004-05-27
KR20050074573A (ko) 2005-07-18
ZA200503805B (en) 2006-09-27
ATE456370T1 (de) 2010-02-15
EP1562612A1 (en) 2005-08-17
CA2504666A1 (en) 2004-05-27
BR0316170A (pt) 2005-09-27
GB0226434D0 (en) 2002-12-18
CN1711094A (zh) 2005-12-21
ES2338109T3 (es) 2010-05-04
JP2006508953A (ja) 2006-03-16
NO20052312L (no) 2005-06-06
US20060142297A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
AU2003279456B2 (en) Combination product of inhibitor of the SRC family of non-receptor tyrosine kinases and gemcitabine
ES2225545T3 (es) Derivados de quinazolina para el tratamiento de tumores.
RU2267489C2 (ru) Производные хиназолина, способ их получения и фармацевтическая композиция
US20100029673A1 (en) Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use
CN116710094A (zh) 包含kras g12c抑制剂的药物组合以及kras g12c抑制剂用于治疗癌症的用途
US20030225111A1 (en) Therapy
ES2272737T3 (es) Derivados de quinolina y su uso como inhibidores de tirosina quinasas.
ES2312557T3 (es) Derivados de quinazolina.
HK1204575A1 (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
ZA200309165B (en) 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors.
EP1786265A2 (en) Novel compositions and methods of treatment
KR20040103964A (ko) 암 치료를 위한 조합 요법
US8952019B2 (en) Methods of using selective chemotherapeutic agents for targeting tumor cells
CN114828842A (zh) 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
MXPA05005119A (es) Producto de combinacion de inhibidor de la familia src de cinasas de tirosina de no receptor y gemcitabina.
MXPA06013635A (es) Metodo para el tratamiento de cancer.
HK40028536A (en) Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
WO2018106118A1 (en) Treatment of diffuse intrinsic pontine glioma
JP2014034533A (ja) Ｈｓｐ９０阻害剤とｅｇｆｒチロシンキナーゼ阻害剤の組み合わせ
HK1147173A (en) Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired